Host: Jennifer Caudle, DO <br>

Guest: Robert L. Zanni, MD, CPI <br>

Airway clearance is the primary therapy for patients with cystic fibrosis. In this activity, Dr. Zanni will discuss the rationale for performing airway clearance, as well as current mechanical and pharmacologic choices for patients. He will also discuss airway clearance therapies that are making their way through the pipeline.

Host: Jennifer Caudle, DO Guest: Robert L. Zanni, MD, CPI Airway clearance is the primary therapy for patients with cystic fibrosis. In this activity, Dr. Zanni will discuss the rationale for performing airway clearance, as well as current mechanical and pharmacologic choices for patients. He will also discuss airway clearance therapies that are making their way through the pipeline.

Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis

Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive.
The Cystic Fibrosis in Focus series gathers the latest information from leading medical experts devoted to advancing knowledge in pursuit of treating patients with CF. With education spanning topics such as pinpointing CF's underlying genetic basis, identifying specific mutations, improving clinical detection methods, and providing more targeted therapies, The Cystic Fibrosis in Focus series delivers the critical tools needed to improve care for CF patients.​
In Partnership with

Medicine

Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive. The Cystic Fibrosis in Focus series gathers the latest information from leading medical experts devoted to advancing knowledge in pursuit of treating patients with CF. With education spanning topics such as pinpointing CF's underlying genetic basis, identifying specific mutations, improving clinical detection methods, and providing more targeted therapies, The Cystic Fibrosis in Focus series delivers the critical tools needed to improve care for CF patients.​ In Partnership with

Cystic fibrosis (CF) is one of the most prevalent global congenital disorders, affecting some 70,000 individuals worldwide and 30,000 children and adults in the United States. While clinical efforts are expanding worldwide to improve diagnostic testing and treatment approaches for this progressive lung disease, targeted therapies for CF against any specific mutation remain elusive.
The Cystic Fibrosis in Focus series&nbsp;gathers the latest information from leading medical experts devoted to advancing knowledge in pursuit of treating patients with&nbsp;CF. With education spanning topics such as pinpointing CF's underlying genetic basis, identifying specific mutations, improving clinical detection methods, and providing more targeted therapies, The Cystic Fibrosis in Focus series&nbsp;delivers the critical tools needed to improve care for CF patients.​
In Partnership with

Share Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis

Sign up to save your podcasts

Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis

Rationale for Performing Airway Clearance for Patients with Cystic Fibrosis